Physicians' Academy for Cardiovascular Education

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands

U-prevent predicts lifetime risk of CV events in healthy individuals

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?

3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

Direct Factor Xa inhibitor does not mitigate worsening of heart failure in HFrEF patients

3' education - Aug. 27, 2018 - Prof. Faiez Zannad, Vandoeuvre Les Nancy, France

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands
Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.

ESC 2018 Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.

Meeting Impression | PCSK9 inhibition: Science, outcomes & guidance

August 25, 2018 - Munich, Germany
August 25, 2018 - Munich, Germany

Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA
Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.

ESC 2018 Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands
Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.

ESC 2018 Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.

U-prevent predicts lifetime risk of CV events in healthy individuals

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands
Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.

ESC 2018 Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA
Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.

Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Population screening for atrial fibrillation with a smartphone

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium
Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.

ESC 2018 Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.

Summary | Targeting PCSK9 in clinical practice: Guidance & future

Munich, Berlin - August 25, 2018

This is a summary of the presentation by John Kastelein, in which he discusses targeting PCSK9 in clinical practice, focusing on issues surrounding prescription of PCSK9 monoclonal antibodies.

Summary | Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

Munich, Berlin - August 25, 2018

This is a summary of the presentation by Jennifer Robinson, in which she explains that the greatest benefit of PCSK9 antibodies can be obtained at higher LDL-c levels, as seen in high-risk populations.

Summary | PCSK9 as target for treatment: The genetic validation

Munich, Berlin - August 25, 2018

This is a summary of the presentation by Brian Ference, in which he shows data suggesting that PCSK9 inhibitors and statins have biologically and therapeutically equivalent effects on the risk of CVD.

ESC 2018
ESC 2018